Press Releases
-
NOV 13 2018
-
-
NOV 07 2018
ONC201 Investigator Meeting and Clinical Efficacy in H3 K27M-mutant Glioma to be Presented at Society for Neuro-Oncology Conference
Philadelphia, PA (November 6, 2018) – Oncoceutics, Inc. announced that it will host an investigator meeting and that initial efficacy data of its lead compound ONC201 in patients with H3 K27M-mutant gliomas will be presented at the 2018 Annual Meeting of the Society for Neuro-Oncology in New Orleans, on November 15th to November 18th. The
-
-
SEP 10 2018
NCI and Musella Foundation Award Grants for ONC201 Trials in Adult and Pediatric Brain Tumors
Philadelphia, PA (September 10, 2018) – Oncoceutics, Inc. announced the receipt of a Small Business Innovation Research (SBIR) Phase IIB Bridge Award from the National Cancer Institute (NCI). The NCI SBIR Bridge Award will allow Oncoceutics to expand and accelerate its clinical trials evaluating ONC201 in patients with a specific type of lethal brain cancer
-
-
AUG 06 2018
Clinical Cancer Research Article Describes Opportunity to Use Imipridones for Brain Tumors
Philadelphia, PA (July 31, 2018) – Oncoceutics, Inc. announced the publication of a scientific research article in the journal Clinical Cancer Research that demonstrates utility for the company’s imipridone portfolio of compounds in neuro-oncology. Oncoceutics developed this portfolio of chemical compounds that target G protein-coupled receptors (GPCRs) using the unique core chemical structure of the
-
Business Development
© Copyright 2016 Oncoceutics, Inc. All Rights Reserved.